FastMarket.news

CPKC Secures New Labor Agreements with Teamsters Canada Rail Conference

Published 1 days agoCP
CPKC Secures New Labor Agreements with Teamsters Canada Rail Conference

Canadian Pacific Kansas City (CPKC) has reached new collective bargaining agreements with two units from the Teamsters Canada Rail Conference. These agreements aim to enhance wages and benefits for thousands of employees across Canada.


For the Maintenance of Way Employees Division (TCRC-MWED), a new four-year collective agreement has been signed, affecting approximately 2,300 engineering service employees. This development was praised by CPKC's CEO, Keith Creel, who noted the agreement brings long-term labor stability and ensures safe and efficient work operations. Meanwhile, a similar agreement has been reached with the Clerical and Intermodal Employees, represented by the United Steelworkers. This agreement impacts about 600 employees and guarantees higher wages and better benefits.


These labor agreements underline CPKC's dedication to maintaining strong labor relations and stable operations. CEO Keith Creel commented on the importance of these agreements in supporting the North American economy and fostering positive employee relations across the company.

Share this article

Recent Articles

Indivior Shifts Primary Listing from London to Nasdaq

Indivior Shifts Primary Listing from London to Nasdaq

10 minutes agoINDV

Indivior PLC, known for its specialty in treatments for substance use disorders, is set to change its primary stock market listing from the London Stock Exchange (LSE) to the Nasdaq Stock Market. The move follows overwhelming shareholder approval, with the transition officially taking effect on June 27, 2024. As reported by Nasdaq, this decision marks a significant step for the company as it aligns its operations closer to its primary market. Despite this shift, Indivior will retain a secondary listing on the LSE, ensuring UK investors remain engaged with the company. This dual listing strategy allows Indivior to leverage its existing investor base in the United Kingdom while predominantly trading in its most lucrative market. According to Shares Magazine, the new Nasdaq primary listing reflects the company's concentration on maximizing opportunities in the U.S. Indivior generates around 81% of its sales in the United States, underscoring the strategic rationale for the move. As City A.M. notes, this transition also mirrors a wider trend of UK firms considering primary listings in the U.S., which could have long-term implications for the competitiveness of London's financial markets. Indivior's shift to Nasdaq demonstrates its intent to capitalize on growth opportunities within its largest market sector.

Qualcomm Gets 2025 Extension for Alphawave Takeover Bid

Qualcomm Gets 2025 Extension for Alphawave Takeover Bid

40 minutes agoQCOM

Qualcomm has been granted additional time to make a formal takeover bid for Alphawave IP Group, with the UK Takeover Panel extending the deadline until May 27, 2025. This move reflects ongoing negotiations between the two companies, as Qualcomm explores the acquisition potential of Alphawave, noted for its influential 'serdes' technology used in AI processors. The discussions between Qualcomm and Alphawave have been confirmed by Alphawave, highlighting the strategic interest in Alphawave's technological assets. According to Reuters, this extension and ongoing discussions underscore the importance and complexity of such a high-stakes acquisition in the tech industry. Regulatory considerations are also a significant part of the extended timeline, allowing both parties ample time to navigate these intricacies. Meanwhile, Qualcomm's stock (ticker: QCOM) experienced a minor decrease in its market value. As of May 31, 2025, the stock traded at $145.20, marking a decrease of $3.20 or 2.16% down from the previous close. Qualcomm remains a key player in the tech sector, and this potential acquisition marks a strategic step in expanding its reach in the semiconductor industry.

Tesla's Sales Plunge in Sweden Amid Rising Competition

Tesla's Sales Plunge in Sweden Amid Rising Competition

55 minutes agoTSLA

Tesla's vehicle registrations in Sweden saw a dramatic drop in May 2025, with new car registrations falling 53.7% year-on-year to 503 vehicles, as reported by Mobility Sweden. This marks a significant decline for the company in the Swedish market, highlighting challenges amidst a dynamic European automotive landscape. Reuters reported this notable decrease, which has positioned Tesla in a tougher spot within the regional market offerings. This downturn has impacted Tesla's market share in Sweden, reflecting broader sales reductions across Europe. The decline is part of a trend seen as the electric vehicle market becomes increasingly competitive. Swedish companies like Polestar, along with international brands, are capitalizing on this environment by delivering attractive alternatives to Tesla's vehicles. The context includes a mix of factors influencing Tesla's situation in Sweden. Public perception of Tesla has been swayed by CEO Elon Musk's political engagements, which have been interpreted variably by consumers in the region. Despite the overall growth in Sweden's car market—with a 14% annual increase in new car registrations as of January 2025—Tesla's sales woes are more about brand-specific issues rather than a market-wide trend.

Novartis' Pluvicto Shows Promise in Treating Early-Stage Prostate Cancer

Novartis' Pluvicto Shows Promise in Treating Early-Stage Prostate Cancer

1 hours agoNVS

Novartis' radiopharmaceutical therapy, Pluvicto, is making strides in the treatment of metastatic prostate cancer that's still responsive to hormone therapy. A recent late-stage clinical trial revealed that Pluvicto offers a 'clinically meaningful benefit' in progression-free survival for these patients, signifying a potential advance in cancer care. Currently, Pluvicto is approved for cases where prostate cancer no longer responds to hormone treatments, but this new data could pave the way for earlier intervention. Reuters reported that this shift could meet a significant unmet need in treating prostate cancer, offering hope to many patients facing limited options. Novartis expects to present detailed trial results at an upcoming medical conference and is planning to seek broader regulatory approval in the latter half of 2025. Financially, Pluvicto generated $371 million in revenue during the first quarter of 2025, marking a 20% increase from the previous year, underscoring its growing importance in the company's portfolio.